DelveInsight’s “Microsatellite Stable Colorectal Cancer Market Insights, Epidemiology, and Market Forecast- 2032” report delivers an in-depth understanding of the Microsatellite Stable Colorectal Cancer, historical and forecasted epidemiology as well as the Microsatellite Stable Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis @ Microsatellite Stable Colorectal Cancer Therapeutics Market Outlook

Key Takeaways from the Microsatellite Stable Colorectal Cancer Market Report

• On March 24, 2026- Kahr Bio Australia Pty Ltd initiated a clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
• On March 20, 2026- Incyte Corporation conducted a phase 3 study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
• On March 12, 2026- GlaxoSmithKline initiated a phase 2 study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for “capecitabine + oxaliplatin”) to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as “neoadjuvant therapy.” . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will also look at specific signs in the blood and tumor to see if they can help predict how well the treatment is working. This could help better understand how dostarlimab contributes to the response of the disease to treatment.
• On March 09, 2026- NeoImmuneTech announced a Phase 1b/2a study of NT-I7 in combination with pembrolizumab. The study consists of a dose escalation phase (Phase 1b) followed by a dose expansion phase (Phase 2a) and a Biomarker Cohort.
• On March 06, 2026- BioNTech SE initiated a study will test a new treatment called BNT314, which is designed to help the body’s immune system fight cancer in combination with another new treatment (BNT327, which is an immune checkpoint inhibitor) and chemotherapy in participants with metastatic colorectal cancer (mCRC).
• On March 02, 2026- Medimmune LLC announced a Phase 1b/2, open-label, multicenter, randomized, multidrug platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) in combination with novel oncology therapies in patients with first-line metastatic MSS-CRC. The study is designed to concurrently evaluate potential novel combinations with clinical promise using a 2-part approach. Part 1 is a Phase 1b study of safety, and Part 2 is a Phase 2 study of efficacy and safety.
• Approximately 85 percent of instances of non-metastatic colorectal cancer (CRC) are associated with chromosomal instability and a proficient DNA Mismatch-Repair mechanism (pMMR); these cases are also known as CRC with microsatellite stability (MSS).
• In the United States, an estimated 104,610 new cases of colon cancer and 43,340 cases of rectal cancer will be diagnosed in 2020
• Men have a 30% greater CRC incidence rate than women.
• In their lifetime, around 4.4 percent of males (1 in 23) and 4.1 percent of women (1 in 25) will be diagnosed with CRC. Lifetime risk is equivalent in men and women, despite greater incidence rates in males because of women’s longer life expectancy.
• The relative survival rate for Colorectal cancer is 64 percent after 5 years of diagnosis and 58 percent after 10 years of diagnosis.
• The leading Microsatellite Stable Colorectal Cancer Companies such as Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.
• Promising Microsatellite Stable Colorectal Cancer Pipeline Therapies such as Lenvatinib, Pembrolizumab (KEYTRUDA®), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.

Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Microsatellite Stable Colorectal Cancer Treatment Market Size

Microsatellite Stable Colorectal Cancer Epidemiology Segmentation in the 7MM

The epidemiology section of Microsatellite Stable Colorectal Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Microsatellite Stable Colorectal Cancer epidemiology trends @ Microsatellite Stable Colorectal Cancer Prevalence

Microsatellite Stable Colorectal Cancer Drugs Market

The Microsatellite Stable Colorectal Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Microsatellite Stable Colorectal Cancer signaling in Microsatellite Stable Colorectal Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.

Microsatellite Stable Colorectal Cancer Treatment Market Landscape

The Microsatellite Stable Colorectal Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Microsatellite Stable Colorectal Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Microsatellite Stable Colorectal Cancer treatment guidelines, visit @ Microsatellite Stable Colorectal Cancer Market Drivers and Barriers

Microsatellite Stable Colorectal Cancer Companies

Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec and others.

Microsatellite Stable Colorectal Cancer Market Outlook

The report’s outlook on the Microsatellite Stable Colorectal Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Microsatellite Stable Colorectal Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Microsatellite Stable Colorectal Cancer drug and late-stage pipeline therapy.

Microsatellite Stable Colorectal Cancer Drugs Uptake

The drug chapter of the Microsatellite Stable Colorectal Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Microsatellite Stable Colorectal Cancer.

From market size to emerging drugs—find it all in our latest report. Read now! @ Microsatellite Stable Colorectal Cancer Ongoing Clinical Trials Analysis

Scope of the Microsatellite Stable Colorectal Cancer Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Microsatellite Stable Colorectal Cancer Companies- Gritstone Oncology, Merck Sharp & Dohme Corp, Arrys Therapeutics, NeoImmuneTec, and others.
• Microsatellite Stable Colorectal Cancer Pipeline Therapies- Lenvatinib, Pembrolizumab (KEYTRUDA®), GI-101, Docetaxel, BMS-986340, Nivolumab, FOG-001, Balstilimab, Botensilimab and others.
• Microsatellite Stable Colorectal Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Microsatellite Stable Colorectal Cancer Unmet Needs, KOL’s views, Analyst’s views, Microsatellite Stable Colorectal Cancer Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Executive Summary of Microsatellite Stable Colorectal Cancer

3. Competitive Intelligence Analysis for Microsatellite Stable Colorectal Cancer

4. Microsatellite Stable Colorectal Cancer: Market Overview at a Glance

5. Microsatellite Stable Colorectal Cancer: Disease Background and Overview

6. Microsatellite Stable Colorectal Cancer Patient Journey

7. Microsatellite Stable Colorectal Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Microsatellite Stable Colorectal Cancer Unmet Needs

10. Key Endpoints of Microsatellite Stable Colorectal Cancer Treatment

11. Microsatellite Stable Colorectal Cancer Marketed Products

12. Microsatellite Stable Colorectal Cancer Emerging Therapies

13. Microsatellite Stable Colorectal Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Microsatellite Stable Colorectal Cancer Market Outlook

16. Access and Reimbursement Overview of Microsatellite Stable Colorectal Cancer

17. Microsatellite Stable Colorectal Cancer KOL Views

18. Microsatellite Stable Colorectal Cancer Market Drivers

19. Microsatellite Stable Colorectal Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market